Last €1.74 EUR
Change Today -0.037 / -2.08%
Volume 1.0K
EZBG On Other Exchanges
Symbol
Exchange
EN Brussels
Stuttgart
As of 8:46 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

eckert-ziegler bebig (EZBG) Snapshot

Open
€1.78
Previous Close
€1.78
Day High
€1.78
Day Low
€1.72
52 Week High
01/31/14 - €2.30
52 Week Low
08/12/13 - €1.70
Market Cap
30.5M
Average Volume 10 Days
1.2K
EPS TTM
€0.20
Shares Outstanding
17.6M
EX-Date
--
P/E TM
8.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for ECKERT-ZIEGLER BEBIG (EZBG)

Related News

No related news articles were found.

eckert-ziegler bebig (EZBG) Related Businessweek News

No Related Businessweek News Found

eckert-ziegler bebig (EZBG) Details

Eckert & Ziegler BEBIG s.a. develops, manufactures, and sells radiation equipment and related products and components based on isotope technology. The company offers IsoSeed, a seed implant for the treatment of prostate cancer; IsoCord, a seed chain with up to 70 seeds in a magazine that provides optimal radiation protection; IsoStrand, which consists of 10 IsoSeed spaced 1 cm apart; Permanent Seed Implant Dosimetry, a software for prostate brachytherapy; needles for LDR brachytherapy; and AnchorSeed, a loose seed with a bioabsorbable encapsulation. It also provides MultiSource, a HDR (high dose rate) afterloader system for the HDR brachytherapy applications; GyneSource, a five channel HDR afterloader developed for gynaecological brachytherapy treatments; HDR applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mould treatments; and HDRplus, a software that delivers HDR treatment plan. In addition, the company offers products for the temporary brachytherapy of eye cancers, including Ru-106 Eye Applicators, a brachytherapy source that is used in the treatment of uveal melanoma, retinoblastoma, and melanoma of the iris, as well as for other applications; I-125 Ophthalmic Seeds for use in COMS Eye Applicators to treat intraocular tumors, such as uveal melanoma or retinoblastoma; and Plaque Simulator, a software for 3D virtual simulation of ophthalmic plaque radiotherapy. Further, it provides radiotherapy accessories. The company offers its products to oncologists, radiologists, urologists, and medical physicists through a network of distributors and agents worldwide. The company was formerly known as International Brachytherapy s.a. and changed its name to Eckert & Ziegler BEBIG S.A. in June 2011. Eckert & Ziegler BEBIG s.a. was founded in 1996 and is headquartered in Seneffe, Belgium. Eckert & Ziegler BEBIG s.a. is a subsidiary of Eckert & Ziegler AG.

200 Employees
Last Reported Date: 05/6/14
Founded in 1996

eckert-ziegler bebig (EZBG) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: €281.4K
Managing Director, Director and Member of Man...
Total Annual Compensation: €163.1K
Compensation as of Fiscal Year 2013.

eckert-ziegler bebig (EZBG) Key Developments

Eckert & Ziegler Bebig Announces Consolidated Interim Statement for the First Quarter Ended March 31, 2014

Eckert & Ziegler BEBIG announced consolidated interim statement for the first quarter ended March 31, 2014. For the period, the company's sales were EUR 6.5 million considerably higher compared to EUR 5.5 million in the prior year. The increase in sales is exclusively a result of the recently acquired business in the US.

Eckert & Ziegler BEBIG S.A. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Eckert & Ziegler BEBIG S.A. reported consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company's operating loss was EUR 842,000 compared to operating result of EUR 968,000 a year ago. Loss before interest and taxes was EUR 842,000 compared to income before interest and taxes of EUR 968,000 a year ago. Loss before tax was EUR 1,007,000 compared to profit before tax of EUR 978,000 a year ago. Net loss was EUR 705,000 or EUR 0.04 per diluted share compared to net profit of EUR 632,000 or EUR 0.04 per diluted share a year ago. Cash inflow generated from operating activities was EUR 122,000 compared to cash outflow generated from operating activities of EUR 178,000 a year ago. Additions of intangible non-current assets was EUR 299,000 compared to EUR 237,000 a year ago. Additions of tangible non-current assets was EUR 202,000 compared to EUR 168,000 a year ago. Net debt increased slightly by EUR 0.3 million, totaling EUR 6.8 million at the reporting date compared to EUR 6.5 million on December 31, 2013.

Eckert & Ziegler BEBIG Reports Consolidated Earnings Results for the Full Year Ended December 31, 2013

Eckert & Ziegler BEBIG reported consolidated earnings results for the full year ended December 31, 2013. For the year, the company reported sales were EUR 27.8 million, compared to EUR 31.8 million in 2012, a decrease of 12.4%. Diluted earnings per share were decreased from EUR 0.22 to EUR 0.20 in 2012. Operating result was EUR 2.165 million against EUR 5.263 million a year ago. Earnings before interest and taxes were EUR 1.958 million against EUR 5.222 million a year ago. Profit before tax was EUR 2.555 million against EUR 4.837 million a year ago. Net profit was EUR 3.460 million against EUR 3.869 million a year ago. EBITDA was EUR 4.893 million against EUR 7.527 million a year ago. Net debt was EUR 6.549 million as on that date against EUR 1.275 million a prior year period. Book value per share was EUR 2.64 as on that date against EUR 2.45 a prior year period. Cash inflow generated from operating activities was EUR 3.158 million against EUR 4.079 million a year ago. Additions to intangible non-current assets were EUR 1.255 million against EUR 0.954 million a year ago. Additions to tangible non-current assets was EUR 0.697 million against EUR 0.774 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EZBG:BB €1.74 EUR -0.037

EZBG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Varian Medical Systems Inc $81.49 USD -0.66
View Industry Companies
 

Industry Analysis

EZBG

Industry Average

Valuation EZBG Industry Range
Price/Earnings 14.3x
Price/Sales 1.1x
Price/Book 0.7x
Price/Cash Flow 14.3x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT-ZIEGLER BEBIG, please visit www.bebig.eu/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.